https://submit.hematology.org/program/presentation/671797
ASH’s real-world MDS data from 1429 patients makes for grim reading, showing how weak current treatments (Aza, Deci, and Vene) are:
1L ORR 31%, 3L 20%, 4L 14%, very high-risk OS only 11 months
“Conclusions: In a large population of patients with MDS treated in the real-world setting, our study provides critical insights on the treatment patterns and outcomes of patients with MDS. These findings underscore poor outcomes for patients who are high risk at diagnosis and those who exhaust early treatment approaches. More importantly, our findings demonstrate the need for new therapeutic approaches for this group of patients.”
BEXMAB, with its ASH25 publications, is in a completely different league and brings a significant improvement… which is what the FDA wants for BTD/AA status.
No need to try to convince me it’s uncertain, etc.
At this point, Zeidan, Zeidner, Daver, and Badar are enough for me.